Fiche vierge modèle

583837 Commentaires

• double Pushchair sale mardi, 10 décembre 2024 22:41

  See What Double Pushchair Sale Tricks The Celebs Are Using double
  Pushchair sale

  Lien vers le commentaire
• botdb.win mardi, 10 décembre 2024 22:40

  10 Things Everyone Hates About Integrated Combi Fridge Freezer
  built in fridge freezer 70/30 (botdb.win)

  Lien vers le commentaire
• Mammie mardi, 10 décembre 2024 22:40

  How To Create An Awesome Instagram Video About Double Glazing Misting Repair double glazed repair (Mammie)

  Lien vers le commentaire
• Scotty mardi, 10 décembre 2024 22:39

  How To Tell If You're In The Right Place To
  Go After 3 Wheel Vs 4 Wheel Rollator stylish 3 wheel walker (Scotty)

  Lien vers le commentaire
• Mazda Key Fob Repair mardi, 10 décembre 2024 22:38

  Watch Out: How Mazda Replacement Keys Is Taking Over And What Can We Do About It Mazda
  Key Fob Repair

  Lien vers le commentaire
• Item Upgrader mardi, 10 décembre 2024 22:38

  11 Ways To Fully Redesign Your Item Upgrade Item Upgrader

  Lien vers le commentaire
• Mesothelioma lawsuit mardi, 10 décembre 2024 22:37

  The Best Advice You'll Ever Get About Asbestos Mesothelioma Mesothelioma lawsuit

  Lien vers le commentaire
• iqos bangkok mardi, 10 décembre 2024 22:37

  PMI's US launch of flagship IQOS device needs FDA green light
  
  *
  
  Six health campaign groups wrote letter to FDA criticising PMI Say
  PMI misrepresented past FDA decisions on IQOS
  
  *
  
  PMI says it discusses its products in accordance with law
  
  *
  
  FDA acknowledges receiving campaigners' letter
  
  (Updates headline)
  
  By Emma Rumney
  
  LONDON, July 16 (Reuters) - Health campaigners have
  written to U.S. regulators accusing Philip Morris International
  of misrepresenting past regulatory decisions, seeking to disrupt the launch of its
  flagship heated tobacco device IQOS in the United States.
  
  
  The world's biggest tobacco company by market value has spent billions
  of dollars developing the product, which investors see as key
  to driving future growth. But it needs permission from the U.S.
  Food and Drug Administration to sell it in the world's second
  largest tobacco market by revenue.
  
  Six anti-tobacco and health groups, including the Campaign for Tobacco-Free Kids, the American Academy of Pediatrics and the American Lung Association, wrote to the FDA to oppose IQOS-related applications PMI
  has submitted to the agency.
  
  "PMI has repeatedly made misleading and deceptive statements wrongly suggesting that the FDA has found that IQOS reduces the risk of disease,"
  the letter, dated June 27 and reviewed by Reuters, said.
  
  
  The campaign groups allege that PMI violated the FDA's orders by suggesting IQOS offered lower risks than cigarettes.
  
  Their letter cited four examples of such statements in the United States, the Philippines, Mexico and Kazakhstan.
  
  They also said in the letter that upcoming
  independent studies contradict PMI's findings about how many IQOS users completely switch to the device from cigarettes.
  
  
  Presentations on the studies from the International
  Tobacco Control Project (ITC) at Canada's University of Waterloo are attached to the letter as
  exhibits.
  
  They show the ITC found a far lower rate of IQOS users had quit smoking in Japan and Korea than estimates from PMI.
  
  
  These factors "directly bear on whether PMI should be permitted to market IQOS" in the
  United States, the campaigners' letter said.
  
  The contents of the letter have not been previously reported.
  
  
  Asked by Reuters to respond to the letter, a PMI spokesperson said the company was proud to discuss the FDA's conclusions on IQOS.
  
  
  The spokesperson did not initially address each example but said some of the language flagged by campaigners was, in the company's view, compatible with the FDA's orders.
  
  On Tuesday, the spokesperson added that this was true all of
  the language cited in the campaigners' letter.
  
  "Wherever we discuss our science and our products, we do so in accordance with all applicable laws," the spokesperson said.
  
  
  
  Reuters could not determine whether the campaigners' letter would change the FDA's approach
  to IQOS. The agency said it had received the letter and would respond directly to the senders.
  It did not comment further.
  
  Devices like IQOS heat up sticks of ground tobacco without burning them in an attempt to avoid the harmful
  chemicals released via combustion.
  
  The FDA first authorised PMI to sell an older version of IQOS in 2019.
  It subsequently authorised the company to market it as offering reduced exposure to harmful chemicals versus
  cigarettes for smokers who completely switch - known as an "exposure modification order".
  
  
  The FDA can also issue a "risk modification order", authorising a
  company to claim its product reduces the risk of tobacco-related harm and disease.
  
  But this is harder to prove, especially without long-term, epidemiological studies.
  
  
  The FDA rejected PMI's previous application to say its older IQOS device
  results in reduced health risks, saying there
  wasn't sufficient evidence to support this.
  
  PMI applied in 2023 to renew its existing exposure modification orders.
  
  Later that year, it also applied to sell and market a newer
  version of the IQOS device in the same way. The FDA has yet to decide on these applications.
  
  
  Marketing the product as having health benefits compared to traditional cigarettes could help PMI persuade consumers to switch
  as well as afford it tax benefits versus cigarettes in some U.S.
  states.
  
  PMI is preparing to sell an older IQOS device in four U.S.
  cities. However, it has said it will not pursue a full U.S.
  launch until the newer version of its device gets FDA authorisation.
  
  SWITCH RATES
  
  The campaign groups also cited preliminary data from ITC studies in Japan and Korea, saying it contradicted PMI's findings about how many
  IQOS users completely switch from cigarettes.
  
  The studies have been presented at academic conferences but have not yet been submitted for publication in a journal, ITC researchers told Reuters.
  As a result, study abstracts have been peer reviewed but the full findings have
  yet to go through that process.
  
  Japan is IQOS' largest market and the introduction of heated tobacco there coincided with an accelerated decline in cigarette sales.
  
  
  PMI estimates more than seven out of 10 of its registered IQOS customers globally have quit cigarettes.
  A 2023 PMI application to the FDA emphasised that the majority of
  IQOS users were using IQOS exclusively.
  
  However, the ITC's researchers put the percentage of all
  IQOS users that had quit smoking at just 15% in Japan and 30% in Korea in 2021.
  
  
  Users most commonly used IQOS and cigarettes simultaneously, known as "dual use", often leading to an overall increase
  in tobacco consumption, the ITC researchers found.
  
  PMI pointed to a 2019 Japanese government health survey,
  where 75% of respondents who reported using heated tobacco said they did not smoke.
  
  
  However, a paper published this year, led by researchers from Georgetown University, highlighted flaws in the
  government's survey, including changes to the question format that can lead
  to under-reporting of smoking.
  
  Other surveys have also found higher rates of dual use than the government, it said.
  
  
  (Reporting by Emma Rumney; Editing by Matt Scuffham and Emelia
  Sithole-Matarise)

  Lien vers le commentaire
• cây bồ kết mardi, 10 décembre 2024 22:37

  I am now not positive the place you are getting your information, but great topic.
  
  I needs to spend some time studying more or figuring out more.
  Thanks for fantastic info I was searching for this information for my mission.

  Lien vers le commentaire
• french Doors glass Replacement mardi, 10 décembre 2024 22:37

  Guide To French Doors Glass Replacement: The Intermediate
  Guide For French Doors Glass Replacement french Doors glass Replacement

  Lien vers le commentaire